| 1. |
Feyissa AM, Mirro EA, Wabulya A, et al. Brain-responsive neurostimulation treatment in patients with GAD65 antibody-associated autoimmune mesial temporal lobe epilepsy. Epilepsia Open, 2020, 5(2): 307-313.
|
| 2. |
樊雪梅, 李鑫鑫, 黃賢會, 等. 抗谷氨酸脫羧酶65抗體相關癲癇發作的研究進展. 癲癇雜志, 2021, 7(3): 246-251.
|
| 3. |
樊雪梅. 抗GAD65抗體相關癲癇發作的臨床異質性研究. 吉林大學, 碩士學位論文, 2021.
|
| 4. |
Dade M, Berzero G, Izquierdo C, et al. Neurological syndromes associated with Anti-GAD antibodies. Int J Mol Sci, 2020, 21(10): 3701.
|
| 5. |
Conde-Blanco E, Pascual-Diaz S, Carre?o M, et al. Volumetric and shape analysis of the hippocampus in temporal lobe epilepsy with GAD65 antibodies compared with non-immune epilepsy. Sci Rep, 2021, 11(1): 101-109.
|
| 6. |
Vinke AM, Schaper FLWVJ, Vlooswijk MCG, et al. Anti-GAD antibodies in a cohort of neuropsychiatric patients. Epilepsy Behav, 2018, 82: 25-28.
|
| 7. |
Dalakas MC, Li M, Fujii M, et al. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology, 2001, 57(5): 780-784.
|
| 8. |
Chengyu L, Weixiong S, Chao C, et al. Clinical features and immunotherapy outcomes of anti-glutamic acid decarboxylase 65 antibody-associated neurological disorders. J Neuroimmunol, 2020, 345: 577289.
|
| 9. |
Langenbruch L, Wiendl H, Gro? C, et al. Diagnostic utility of cerebrospinal fluid (CSF) findings in seizures and epilepsy with and without autoimmune-associated disease. Seizure, 2021, 91: 233-243.
|
| 10. |
Fredriksen JR, Carr CM, Koeller KK, et al. MRI findings in glutamic acid decarboxylase associated autoimmune epilepsy. Neuroradiology, 2018, 60(3): 239-245.
|
| 11. |
王小鵬, 韓曙光, 唐海, 等. 抗GAD65抗體腦炎的臨床特點. 國際感染病學(電子版), 2019, 8(4): 128-129.
|
| 12. |
Di Giacomo R, Deleo F, Pastori C, et al. Predictive value of high titer of GAD65 antibodies in a case of limbic encephalitis. J Neuroimmunol, 2019, 337: 577063.
|
| 13. |
楊樺, 趙敏, 任雪飛, 等. 抗谷氨酸脫羧酶65抗體相關性小腦性共濟失調1例報道. 國際神經病學神經外科學雜志, 2020, 47(1): 85-86.
|
1/5
WeChat